sDMARDs was higher than DAS 28 of 3.2 (availability). While the price of annual treatment with an average sDMARD was never higher than GDP per capita, the price of one year treatment with a bDMARD exceeds the GDP per capita in 26 countries (affordability). More restricted access was associated with higher disease activity and worse physical function. Efforts are needed improve access to rheumatological care across European countries.

Disclosure statement: The author has declared no conflicts of interest.